Video Series

Dr Brose elaborates on treating patients with DTC with lenvatinib, including starting dosage and toxicities/adverse events.

A medical professional discusses Study 211 data and HRQoL analyses for patients with DTC on lenvatinib.

An expert explains the impact of patient age when taking lenvatinib for treatment.

Dr Brose reviews frontline treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Marcia S. Brose, MD, PhD, introduces our first patient case, a 70-year-old woman with differentiated thyroid cancer (DTC).

Lowell Hart, MD, FACP, discusses what he’d like to see in the future for the treatment of ER+ breast cancer and includes a note concerning Ki-67 analyses.

Dr Hart explains his prognosis for our case patient.

Lowell Hart, MD, FACP, lists the different types of adverse events that are common when CDK4/6 inhibitors are used in both the adjuvant and advanced cancer setting.

Dr Hart delves into the CDK4/6 inhibitor clinical trials for breast cancer, some that he’s even participated in.

Dr Hart explains the different adjuvant therapy options for patients with HR+ breast cancer.

Lowell Hart, MD, FACP, introduces our patient case, a 54-year-old woman with ER+/PR+ breast cancer, and discusses his strategy and the risk of recurrence for the disease.

Dan Petrylak, MD, discusses the pros and cons of using abiraterone as a front-line therapy for mCSPC and provides details of the PEACE-1 study.

Dr Petrylak presents our second case, a 62-year-old man with mCSPC.

An expert explains the unmet needs in the mCSPC landscape, as well as key takeaways if you are treating patients with this disease.

Dr Petrylak recalls the study design and results of the TITAN study.

Dan Petrylak, MD, presents our first case for discussion, an 80-year-old man with metastatic castration-sensitive prostate cancer (mCSPC). Front-line therapy options and monitoring for mCSPC are also mentioned.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss possible future developments with BTKi as therapy options in B-cell lymphomas.

Drs Shadman and Cohen introduce new data concerning a third-generation BTK inhibitor, pirtobrutinib, and discuss unmet needs in the B-cell malignancy landscape.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, share their preferences regarding BTK-targeted treatment in B-cell malignancies.

Two experts discuss use of ibrutinib and zanubrutinib and data from the ALPINE and ELEVATE-RR trials.

Drs Shadman and Cohen review clinical trials of zanubrutinib in B-cell lymphomas.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, talk about disease progression on BTKi and what mechanisms of resistance can occur.

The panel of experts share their treatment recommendations for a 64-year-old woman with RET wild-type metastatic MTC.

Dr Marcia Brose reviews key efficacy and safety data from the phase 3 ZETA and EXAM clinical trials.

Marcia Brose, MD, presents the case of a 64-year-old woman with RET wild-type metastatic medullary thyroid cancer.

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, consider potential treatment options for relapsed/refractory diffuse large B-cell lymphoma in the future.

Two experts examine bispecific antibody treatment use for relapsed/refractory diffuse large B-cell lymphoma.

Lori Wirth, MD, discusses the mechanism of action of pralsetinib and key data from the phase 1/2 ARROW clinical trial.

The panel of experts discuss practical considerations regarding selpercatinib and the LIBRETTO-001 and LIBRETTO-531 clinical trial data.

Lori Wirth, MD, discusses the mechanism of action of selpercatinib and key data from the LIBRETTO-001 and LIBRETTO-531 clinical trials.